专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

EP4149428B1 COMBINED HYPEROSMOLAR SOLUTION FOR INFUSION 有权
公开(公告)号：EP4149428B1
公开(公告)日：2024-08-28
申请号：EP21739173.9
申请日：2021-05-12
IPC分类号： A61K9/00 , A61K47/12 , A61P7/08
CPC分类号： A61K9/0019 , A61K9/0026 , A61K47/12 , A61P7/08 , Y02A50/30

2. 发明授权

EP2991627B1 BLOOD SUBSTITUTE COMPOSITION AND METHOD OF USE 有权转让
公开(公告)号：EP2991627B1
公开(公告)日：2018-09-05
申请号：EP14791114.3
申请日：2014-05-05
申请人： Washington University
发明人： LANZA, Gregory M. , PAN, Dipanjan , DOCTOR, Allan , SPINELLA, Philip C.
IPC分类号： A61K9/14 , A61K38/42 , A61K47/30 , A61P7/08 , B82Y5/00 , A61K38/06
CPC分类号： A01N1/0226 , A61K9/0026 , A61K9/107 , A61K9/51 , A61K38/063 , A61K38/42 , B82Y5/00 , A61K2300/00
摘要： The present disclosure provides oxygen-carrying nanoparticles, methods of making the nanoparticles, and methods of using the nanoparticles to carry oxygen in blood.

3. 发明公开

EP3202421A1 O/W-EMULSIONS COMPRISING SEMIFLUORINATED ALKANES 有权转让
标题翻译：包含半氟化烷烃的O / W-乳液
公开(公告)号：EP3202421A1
公开(公告)日：2017-08-09
申请号：EP17159788.3
申请日：2012-01-03
申请人： Novaliq GmbH
发明人： THEISINGER, Bastian , THEISINGER, Sonja , GÜNTHER, Bernhard
IPC分类号： A61K47/24 , A61K9/107 , A61K31/05
CPC分类号： A61K9/107 , A61K9/0014 , A61K9/0019 , A61K9/0026 , A61K9/1075 , A61K31/05 , A61K47/06 , A61K47/24 , A61K47/26
摘要： The invention provides liquid compositions in the form of physically stable emulsions comprising a semifluorinated alkane. The semifluorinated alkane is comprised in the dispersed phase, which may also include an active pharmaceutical ingredient. One of the preferred active ingredients is propofol. The compositions are optionally heat sterilisable and can be used for pharmaceutical or cosmetic product applications, and administered topically, intravenously, or via other routes.
摘要翻译：本发明提供了包含半氟化烷烃的物理稳定乳液形式的液体组合物。半氟化烷烃包含在分散相中，其也可以包含活性药物成分。其中一种优选的活性成分是丙泊酚。所述组合物任选地可加热消毒并可用于药物或化妆品应用，并且可局部，静脉内或经由其他途径施用。

4. 发明授权

EP2506858B1 STÄRKEDERIVATMISCHUNGEN 有权
公开(公告)号：EP2506858B1
公开(公告)日：2017-05-10
申请号：EP10790392.4
申请日：2010-12-06
申请人： B. Braun Melsungen AG
发明人： MEIER, Bernd , JANKOWIAK-MEIER, Iris, Theresia , MEIER, Nele , MEIER, Clara
IPC分类号： A61K31/718 , A61K47/36 , C08B31/10 , C08B33/00 , A61K9/00 , A61P9/08 , A61P9/14
CPC分类号： A61K9/0026 , A61K31/718 , A61K45/06 , C08L3/06 , C08L3/08 , C08L2205/02 , A61K2300/00

5. 发明公开

EP2991640A1 A MULTIPART FLUID SYSTEM AND A SYSTEM FOR CITRATE ANTICOAGUALATION IN AN EXTRACORPOREAL BLOOD CIRCUIT 有权
标题翻译：对于混凝柠檬酸预防流体系统和系统多件IN A血液张福亭
公开(公告)号：EP2991640A1
公开(公告)日：2016-03-09
申请号：EP14721347.4
申请日：2014-04-30
申请人： Gambro Lundia AB
发明人： ÅHL, Petra , GODALY, Gabriela , STERNBY, Jan , WIESLANDER, Anders
IPC分类号： A61K31/194 , A61K31/7004 , A61K33/10 , A61K33/14 , A61K33/42 , A61P7/08 , A61K9/08 , A61M1/34
CPC分类号： A61K33/42 , A61K9/0019 , A61K9/0026 , A61K31/194 , A61K31/225 , A61K31/7004 , A61K33/00 , A61K33/06 , A61K33/10 , A61K33/14 , A61K47/02 , A61M1/1654 , A61M1/1672 , A61M1/342 , A61M1/3434 , A61M1/3437 , A61M1/3441 , A61M1/3672 , A61M1/3675 , A61K2300/00
摘要： The present invention concerns a multipart fluid system for dialysis therapy, wherein the multipart fluid system comprises an anticoagulation fluid and at least one treatment fluid from the group consisting of dialysis fluid and infusion fluids. According to the invention the anticoagulation fluid comprises 15-40 mM citrate; and the at least one treatment fluid comprises 1.5-8 mM citrate and ≧10 mM bicarbonate. The present invention further concerns a system for citrate anticoagulation in an extracorporeal blood circuit.
摘要翻译：本发明涉及多部分流体系统，用于透析治疗，worin选自透析液和输注液的多流体系统抗凝流体的包含与至少一种治疗流体。。据抗凝流体包含15-40 mM柠檬酸盐发明; 和所述至少一个处理流体包括1.5-8 mM柠檬酸盐和≧10mM的碳酸氢盐。本发明还涉及在体外血液回路用于枸橼酸抗凝的系统。

6. 发明公开

EP2991627A1 BLOOD SUBSTITUTE COMPOSITION AND METHOD OF USE 有权转让
标题翻译： VERFAHREN ZUR VERWENDUNG的BLUTERSATZZUSAMMENSETZZEN
公开(公告)号：EP2991627A1
公开(公告)日：2016-03-09
申请号：EP14791114.3
申请日：2014-05-05
申请人： Washington University
发明人： LANZA, Gregory M. , PAN, Dipanjan , DOCTOR, Allan , SPINELLA, Philip C.
IPC分类号： A61K9/14 , A61K38/42 , A61K47/30 , A61P7/08 , B82Y5/00
CPC分类号： A01N1/0226 , A61K9/0026 , A61K9/107 , A61K9/51 , A61K38/063 , A61K38/42 , B82Y5/00 , A61K2300/00
摘要： The present disclosure provides oxygen-carrying nanoparticles, methods of making the nanoparticles, and methods of using the nanoparticles to carry oxygen in blood.
摘要翻译：本公开提供了含氧纳米颗粒，制备纳米颗粒的方法以及使用纳米颗粒在血液中携带氧气的方法。

7. 发明授权

EP2175837B1 MICRO-PARTICLES SUITABLE AS BLOOD-SUBSTITUTE 有权
标题翻译：微粒适合作为血液代用品
公开(公告)号：EP2175837B1
公开(公告)日：2015-03-04
申请号：EP08775058.4
申请日：2008-07-14
申请人： CC-Ery GmbH
发明人： BÄUMLER, Hans , GEORGIEVA, Radostina
IPC分类号： A61K9/16 , A61K47/42 , B01D9/00 , B01J13/14
CPC分类号： A61K9/0026 , A61K9/1611 , A61K9/1694 , A61K9/5052 , A61K9/5073 , A61K31/721 , A61K35/16 , A61K38/1703 , A61K38/28 , A61K38/38 , A61K38/42 , A61K38/4826 , A61K47/42 , A61K47/60 , A61K47/6927 , B01D9/005 , B01J13/14 , C12Y304/21004 , Y10T428/2982 , Y10T428/2989 , Y10T428/2991

8. 发明公开

EP2175718A1 BODY FLUID EXPANDERS COMPRISING N-SUBSTITUTED AMINOSULFONIC ACID BUFFERS 有权转让
标题翻译：含有N-取代氨基磺酸缓冲液的体液扩张剂
公开(公告)号：EP2175718A1
公开(公告)日：2010-04-21
申请号：EP08775818.1
申请日：2008-07-03
申请人： Aqix LTD
发明人： REES, Douglas
IPC分类号： A01N1/02 , A61K47/18
CPC分类号： A61K47/183 , A61K9/0026 , A61K31/047 , A61K31/14 , A61K31/165 , A61K31/198 , A61K31/205 , A61K31/51 , A61K31/7004 , A61K33/14 , A61K38/28 , A61K47/02
摘要： A buffered body fluid expander solution, in which the buffer is a physiologically acceptable buffer that is not an inorganic phosphate buffer, comprises calcium ions and magnesium ions at a concentration ratio of 5:1 to 1:1. The non-phosphate buffer may be a physiologically acceptable N-substituted aminosulfonic acid buffers, especially those having a pKa value in aqueous solution of from 7.1 to 7.5 at 2O0C, and most preferably N-tris(hydroxymethyl) methyl-2-aminoethanesulfonic acid (TES), 3-(N-morpholino) propanesulfonic acid (MOPS), N,N-bis (2-hydroxyethyl)-2-aminoethanesulfonic acid (BES) and combinations thereof. Preferred components include from 100 to 150 (preferably about 135) mmoles/L sodium ions, from 2.5 to 6.2 (preferably about 5) mmoles/L potassium ions, from 0.1 to 2.5 (preferably about 1.25) mmoles/L calcium ions, from 0.4 to 25.0 (preferably about 0.45) mmoles/L magnesium ions, from 96 to 126 (preferably about 118) mmoles/L chloride ions, 2 to 11 mmoles/L (preferably about 10) glucose (preferably D-glucose), from 50 to 150 (preferably about 110) μmoles/L glycerol, from 7 to 15 (preferably about 10) μmoles/L choline, from 5 to 400 (preferably about 300) μmoles/L glutamate (preferably L-glutamate), from 5 to 200 (preferably about 20) μmoles/L aspartate (preferably L-aspartate), from 100 to 2000 (preferably about 400) μmoles/L glutamine (preferably L-glutamine), from 15 to 215 (preferably about 60) μmoles/L pyroglutamate, from 20 to 200 (preferably about 100) μmoles/L arginine (preferably L-arginine), from 1 to 120 (preferably about 40) nmoles/L thiamine pyrophosphate (TPP), from 40 to 70 (preferably about 50) μmoles/L D- or DL or L-carnitine (preferably L-carnitine), and from 5 to 200 (preferably about 28) ml.U./L porcine or human insulin (preferably human insulin). The solutions are useful for the manufacture of medicaments and blood volume expanders, for treating hypovolemia or for treating the loss of extracellular and interstitial fluid in subjects suffering with burns, for treating respiratory and/or metabolic acidosis in a subject, for perfusion of the abdominal cavity during peritoneal dialysis of a subject with acute renal failure or an acute toxicity condition, for preventing and/or ameliorating reperfusion injury, and for delivering a therapeutic, test and/or synergistic agent to a subject, including a biological agent, such as at least one stem cell, peptide or genomic derived protein.
摘要翻译：其中缓冲液是不是无机磷酸盐缓冲液的生理上可接受的缓冲液的缓冲体液增容剂溶液包含浓度比为5：1至1：1的钙离子和镁离子。非磷酸盐缓冲剂可以是生理学上可接受的N-取代氨基磺酸缓冲剂，特别是在20℃下在水溶液中具有7.1-7.5的pKa值的那些，最优选N-三（羟甲基）甲基-2-氨基乙磺酸（ TES），3-（N-吗啉代）丙磺酸（MOPS），N，N-双（2-羟乙基）-2-氨基乙烷磺酸（BES）及其组合。优选的组分包括100-150（优选约135）mmoles / L钠离子，2.5-6.2（优选约5）mmoles / L钾离子，0.1-2.5（优选约1.25）mmoles / L钙离子，0.4 至约25.0（优选约0.45）mmole / L镁离子，96至126（优选约118）mmoles / L氯离子，2至11mmole / L（优选约10）葡萄糖（优选D-葡萄糖）（优选约110）μmoles/ L甘油，7至15（优选约10）μmole/ L胆碱，5至400（优选约300）μmole/ L谷氨酸盐（优选L-谷氨酸盐），5至200 优选约20μmol/ L天冬氨酸（优选L-天冬氨酸），100-2000（优选约400）μmol/ L谷氨酰胺（优选L-谷氨酰胺），15-215（优选约60）μmol/ L焦谷氨酸， 20至200（优选约100）μmole/ L精氨酸（优选L-精氨酸），1至120（优选约40）nmoles / L焦磷酸硫胺素（TPP）， 40至70（优选约50）μmol/ L D-或DL或L-肉毒碱（优选L-肉毒碱）和5至200（优选约28）ml.U./L猪或人胰岛素（优选人胰岛素）。该溶液可用于制造药物和血容量扩张剂，用于治疗血容量不足或治疗患有烧伤的受试者中细胞外液和间质液的损失，用于治疗受试者的呼吸和/或代谢性酸中毒，用于灌注腹部在患有急性肾衰竭或急性毒性症状的受试者的腹膜透析过程中，用于预防和/或改善再灌注损伤，以及用于将治疗剂，测试和/或协同剂递送至受试者（包括生物制剂，例如at 至少一种干细胞，肽或基因组来源的蛋白质。

9. 发明授权

EP1066057B1 HEMOGLOBIN-POLYSACCHARIDE CONJUGATES 有权
标题翻译：血红蛋白多糖结合
公开(公告)号：EP1066057B1
公开(公告)日：2009-12-09
申请号：EP99910061.3
申请日：1999-03-25
申请人： Therapure Biopharma Inc.
发明人： ADAMSON, Gordon, W.
IPC分类号： A61K47/48
CPC分类号： A61K47/61 , A61K9/0026

10. 发明公开

EP1879909A1 STABILISATORMOLEKÜLE-ABGEREICHERTE ALBUMINLÖSUNG 有权
标题翻译： STABILISATOR分子耗尽白蛋白溶液
公开(公告)号：EP1879909A1
公开(公告)日：2008-01-23
申请号：EP06763120.0
申请日：2006-05-11
申请人： Albutec GmbH
发明人： STANGE, Katrin
IPC分类号： C07K1/22 , A61K38/38 , A61K9/00
CPC分类号： A61K38/38 , A61K9/0026 , A61K47/12 , A61K47/183
摘要： The invention relates to a method for producing an aqueous albumin solution from an albumin parent solution containing stabilizer molecules capable of occupying binding sites of the albumin. In order to increase the albumin binding capacity for other molecules, at least a portion of the stabilizer molecules are removed from the albumin of the albumin parent solution and separated out from the albumin parent solution. In order to provide a method of this type, with which a stabilized commercial albumin parent solution can be prepared, in comparison to the prior art, easier, faster, and more economically and to prepare albumin without altering it while removing a large portion of the stabilizers and while increasing the albumin binding capacity, the method comprises the steps in which the albumin parent solution is brought into contact with a solid adsorber material whose affinity to at least a portion, preferably to all of the stabilizer molecules used, is higher than the affinity of the albumin to the corresponding stabilizer molecules, and the albumin solution is separated out from the adsorber material, the method being carried out at a pH value > 3.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式